key: cord-0953191-250b2xxw
authors: Sawyer, Thomas W.
title: N-Acetylcysteine as a Treatment for Sulphur Mustard Poisoning
date: 2020-09-25
journal: Free Radic Biol Med
DOI: 10.1016/j.freeradbiomed.2020.09.020
sha: 08453b80faacb1ced1bc168704e58739ebfcc88b
doc_id: 953191
cord_uid: 250b2xxw

In the long and intensive search for effective treatments to counteract the toxicity of the chemical warfare (CW) agent sulphur mustard (H; bis(2-chloroethyl) sulphide), the most auspicious and consistent results have been obtained with the drug N-acetylcysteine (NAC), particularly with respect to its therapeutic use against the effects of inhaled H. It is a synthetic cysteine derivative that has been used in a wide variety of clinical applications for decades and a wealth of information exists on its safety and protective properties against a broad range of toxicants and disease states. Its primary mechanism of action is as a pro-drug for the synthesis of the antioxidant glutathione (GSH), particularly in those circumstances where oxidative stress has exhausted intracellular GSH stores. It impacts a number of pathways either directly or through its GSH-related antioxidant and anti-inflammatory properties, which make it a prime candidate as a potential treatment for the wide range of deleterious cellular effects that H is acknowledged to cause in exposed individuals. This report reviews the available literature on the protection afforded by NAC against the toxicity of H in a variety of model systems, including its efficacy in treating the long-term chronic lung effects of H that have been demonstrated in Iranian veterans exposed during the Iran-Iraq War (1980-1988). Although there is overwhelming evidence supporting this drug as a potential medical countermeasure against this CW agent, there is a requirement for carefully controlled clinical trials to determine the safety, efficacy and optimal NAC dosage regimens for the treatment of inhaled H.

but also through elevation of extracellular glutamate levels via the cystine/glutamate antiporter and subsequent actions on both N-methyl-D-aspartate (NMDA) and 2-amino-3-hydroxy-5methyl-4-isoxazolepropionate (AMPA) receptors [46, 47, 53] . Studies directed at diseases of the nervous system have concluded that there is positive evidence of NAC efficacy in treating a variety of pathologies. However, it has also been noted that the relatively poor membrane permeability of NAC, particularly in penetrating the blood brain barrier may reduce its value as a treatment. Replacement of NAC's carboxyl group with an amide [54] increases its lipophilicity and allows the resultant N-acetylcysteine amide (NACA, Fig. 5 ) to more easily cross cell membranes, facilitating transport into the blood brain barrier, mitochondria and other cellular constituents. This would decrease the doses required and perhaps also alleviate some of the side effects noted with NAC. Although no human trials have been conducted with this drug, its reported superior bioavailability and antioxidant activities relative to NAC, show great promise [55] [56] [57] [58] .

This report consolidates and reviews evidence from both in vitro (Table 1 ) and in vivo (Table 2) test systems, as well as from clinical trials of H-exposed patients (Table 3) , that support (Table 1) Building on the finding that H forms GSH conjugates [59] [60] [61] , and the well known fact that thiols were protective against the toxicity of alkylating agents, Walker and Smith [62] reported in 1969 that thiol pre-treatment of mouse L-cells was protective against H. More than two decades later Smith and Gross [63] noted that NAC increased cellular GSH levels in vitro that would react with H and decrease its subsequent toxicity, a finding that was consistent with the increased efficacy of the nitrogen mustard cyclophosphamide against tumours with low GSH levels [64] . Follow-up studies using human peripheral blood lymphocytes showed that a 24 hour pre-incubation with 10 mM NAC inhibited the H-induced activation of proteases [65] , while a 48 hour pre-treatment followed by washout significantly attenuated the toxicity of low H concentrations, but not of high concentrations in these same cells [66] . They concluded that increasing intracellular GSH levels by providing substrates such as NAC for its synthesis may provide a pathway for designing prophylactic strategies to protect against H toxicity. Relatively low NAC concentrations (100 µM) were utilized in studies to compare the efficacy of NAC alone [67] or in combination with other drugs against H toxicity [68] . A 30 or 60 min NAC pretreatment followed by washout, of 180 µM H-exposed human skin fibroblast HF2FF cells resulted in significant elevations in cellular viability, GSH levels and catalase activity compared decreased endothelial tube formation [69] . Both compounds exhibited protective effects, but only transiently. Work examining the effect of NAC co-administration with H in a human keratinocyte cell line (HaCaT) showed that 1-10 mM NAC pre-treatment (with no washout) protected against both H-induced apoptotic and necrotic cell death, but ameliorated inflammatory cytokine release only at low H concentrations. One hour NAC pre-treatments followed by removal before H exposure were only slightly protective, while 1 hour post-treatments were ineffective, leading the authors to suggest that most of the protective effects noted in their studies [3] ). N-Acetylcysteine was included in a study examining the protective effects of amifostine and several analogues (DRDE-07, -10, -30, -35) against H and three different nitrogen mustards [75] . Mice were exposed dermally to one LD 50 of agent and the antidote was administered orally; one dose (NAC; 250 mg/kg) 30 min prior to agent exposure and the remaining doses daily for the next 3 or 7 days. At 4 and 8 days body weights, percent spleen weights, haematological endpoints and biochemistry were assessed. Compared to the amifostine analogues, NAC protection was generally poor, or non-existent. The authors discussed that lipophilicity is of critical importance for orally effective drugs and relate the prophylactic effectiveness of their test analogues to their higher fat solubility, enabling them to more easily cross cell membranes and increase penetration into the cells. It would be of interest to examine the efficacy of the more highly lipophilic NACA in this model system. N-Acetylcysteine (1 g/kg) was administered to mice 10 min prior to H treatment and increased survival with a protective ratio of 3.9. However, no additional details were located for this study [76] (cited in Papirmeister and coworkers [3] ). The effect of NAC in reducing H tissue distribution and induced ocular toxicity was investigated in rabbits [77] . While under anaesthesia, a 0.4 µl (0.51 mg, 29 µCi of 14 C-H) droplet of neat H was placed onto the center of the cornea of both eyes.

The eyes were treated with 50 µL of a 10% NAC aqueous solution 10 min prior to H exposure and 10 min after. Sulphur mustard was found to distribute to all eye components, with the highest concentrations in the cornea at all time points (1, 6 and 24 hr after H exposure).

Treatment with NAC reduced the radioactivity in all ocular tissues except the nictitating J o u r n a l P r e -p r o o f membrane. Although NAC treatment reduced eyelid edema, it had no effect on prostaglandin, aqueous protein or GSH content. The authors concluded that "NAC reduced 14 C binding and caused a small reduction in some aspects of HD-induced ocular toxicity" [77] . (Table 1) Several research groups have utilized in vivo and in vitro injury models to examine the effect of NAC on H-induced lung toxicity. In a model using early passage bovine pulmonary artery endothelial cells, H was found to produce significant levels of both apoptotic and necrotic cell death. Pre-treatment with high (50 mM) NAC concentrations followed by washout was found to largely eliminate H-induced apoptotic, but not necrotic cell death [78] , a finding that was later attributed to NAC-induced increases in GSH synthesis and concomitant reduction of nuclear transcription factor NF-κB activation [79] . Rappeneau and co-workers [80] used human bronchial epithelial 6HBE14o-cells to screen a number of drug combinations to protect against H toxicity. N-Acetylcysteine alone (10 mM) or in combination with doxycycline, N,N'dimethylthiourea or hexamethylenetetramine provided protection against co-administered H. conclude that NAC may be useful as a potential treatment for H-induced lung injury [83] . These findings were augmented in additional studies using the same rat model, where nebulized NAC (dose not identified) was administered every two hours for twelve hours after H exposure.

Oxygen saturation levels were improved and pulmonary flow obstruction (50% expiratory flow

[EF50]) was reduced in rats 24 hours after exposure [84] . These results were further supported in a domestic swine model where NAC was also found to protect against inhaled H [85] . Female white domestic swine (49-59 kg) were anaesthetized and baseline measurements taken. Once stabilized, the animals were exposed to H vapour via the endotracheal tube at a target inhaled dose of 100 µg/kg delivered over ten minutes. This study did not make note of any observations at earlier time points.

Early studies used tissue culture models and NAC pre-treatment strategies with or without washout, to demonstrate its protective efficacy against H, and to show that in addition to direct scavenging activity, NAC also served as a substrate for increased GSH synthesis. Ensuing , it has been shown that there may be some differences in the mechanisms of action between these two chemicals [87] and the long-term persistence of NAC protection against H should also be investigated. Given the well demonstrated effectiveness of NAC in protecting against the toxicity of H in a wide range of tissue culture systems, as well as against inhaled H in animal models, it may also be useful to re-examine its potential as a protectant against cutaneously applied H, especially using the more strongly lipophilic NACA. (Table 1) The protective properties of NAC have also been examined with putative H simulants such as the nitrogen mustards and CEES ( Fig. 1 ). Mechlorethamine (HN-2; bis(2-chloroethyl) methylamine, Fig. 1 ) induced apoptotic cell death was reduced in primary C3H murine spleen cultures by the addition of 2.5 mM NAC at the time of treatment, slightly reduced with a 30 min post-treatment, and unaffected with a 60 min post-treatment [88] . In a survey of sulphur containing compounds Valeriote and Grates [89] showed that the colony forming ability of bone marrow cells in a spleen colony assay was enhanced (protection index = 26) when mice were treated with a maximally tolerated dose of NAC (8 mg/mouse, IP) 15 min prior to HN-2 administration (0.3 mg IP), compared to bone marrow cells from animals with no pre-treatment.

Early endothelial cells were isolated from mouse embryoid bodies and used to assess the effects of NAC on chorambucil-induced deficits in wound healing parameters [90] . , 10 mM NAC pre-treatment or coadministration with 500 µM CEES prevented toxicity but had no effect on CEES-induced nitric oxide production. Delaying the NAC treatment for 5 hr yielded much reduced protective effects.

Co-administration of 3-10 mM NAC also reversed several CEES-induced oxidative stress parameters [93] . Similar results were found in the same model system where co-administration of 500 µM CEES and 3-10 mM NAC reduced the adverse effects of the simulant on viability,

[96], as well as mitochondrial superoxide dismutases and membrane potential, and cell-cell communication [97] .

Mice were utilized in work comparing the efficacy of several amifostine derivatives and NAC against H, as well as the closely related CW nitrogen mustard agents HN-1 (bis(2chloroethyl) ethylamine), HN-2 and HN-3 (tris(chloroethyl) amine). Oral administration of NAC (see Section 2.2) was largely ineffective against the topical application of these agents compared to the amofostine derivatives [75] .

In studies using the human bronchial epithelial cell line 16HBE14o-, 10 mM NAC was found to reduce HN-2 induced cell death, but only if present during the exposure [98] . Coadministration of NAC with HN-2 in this culture model resulted in a protective ratio of 4.9, significantly better than that obtained for H (1.6) [80] . The authors concluded that in both cases, protection was mainly due to the direct chemical scavenging of NAC with the agents in the culture medium. Primary human bronchial epithelial cells were used to evaluate the role of oxidative stress and epidermal growth factor receptor (EGFR) activation in CEES-induced cytokine secretion. The elevation of interleukin-6, ROS, protein carbonylation, EGFR phosphorylation and NADPH oxidase activation induced by 200 µM CEES was largely eliminated by a 30 min pre-incubation with NAC [99] . Primary rat alveolar macrophages from bronchoalveolar lavage were incubated with 500 µM CEES with or without antioxidant liposomes containing NAC (final NAC concentration unclear) for 4 hours [100] . Liposomal NAC was shown to significantly reduce the levels of the CEES-induced inflammatory response (CINC-1, IL-1β, IL-6, TNF-α). (Table 2) The oxidative stress known to be produced by H and CEES in the lungs and respiratory tract has also resulted in a series of studies examining the effect of NAC against the pulmonary toxicity caused by IT introduction of CEES (6 mg/kg) into the lungs of guinea pigs or rats.

McClintock and co-workers [101] showed that intravenous pre-treatment (-10 min) of 20 mg/kg NAC in rats elicited protection against CEES-induced lung toxicity at 4 hours (70%), and that treatment was still effective when given up to 90 min after CEES exposure (54% protection).

Studies utilizing liposome encapsulated NAC were carried out in an effort to obtain higher and more persistent drug tissue concentrations [102] . In 4 hour experiments, rats were exposed IT to ~6.0 mg/kg CEES and IT installation of liposomal NAC was found to be effective in reducing lung damage whether administered 10 min before (60%) or 60 min after (55%) CEES treatment [102] . Similar results were also reported in the same rat model system by Hoesel et al., [100] , who showed that liposomal NAC (3 mg) administered IT immediately after CEES treatment was effective in eliminating the short-term effects (4 hr; increased lung permeability and elevated pro-inflammatory mediators in bronchoalveolar lavage fluids) induced by ~6.0 mg/kg CEES.

However, these studies also showed that similar NAC dosing regimens were ineffective in decreasing CEES-induced fibrosis three weeks after exposure, unless α/γ-tocopherol was also included in the liposomal preparations. This study also included a direct comparison of the protective effects of liposomal NAC encapsulation compared to treatment with NAC in solution (3 mg; Dulbecco's phosphate buffered saline) against CEES when administered immediately J o u r n a l P r e -p r o o f after agent treatment. This work indicated that liposomal NAC reduced the CEES-induced leakage of 125 I-albumin from lung parenchyma into the bloodstream at 4 hours by 59%, compared to less than 10% for NAC in solution [100] .

Similar studies to the rat work were carried out using guinea pigs, a species whose lung function and structure are more similar to that of humans than are rats. In animals exposed IT to 0.5-6 mg/kg CEES, although a single 0.5 g dose of NAC administered via gavage just prior to CEES exposure was ineffective, pre-treatment with 0.5g NAC/animal/day in the drinking water As an off-shoot of the above studies, guinea pigs given NAC in their drinking water (0.5g/day/animal) were found to be less prone to CEES-induced hair loss than IT infused CEESonly exposed animals [107] .

N-Acetylcysteine has also been found to be an effective pulmonary protectant in other cases where highly reactive molecular species are produced upon chemical exposure. These include known lung toxicants such as bleomycin [108, 109] , perfluoroisobutene [110] , paraquat [111, 112] and phosgene [113, 114] .

The 

Limited studies exist examining the clinical use of NAC in H-exposed individuals. Iranian clinical trials have been carried out examining the effect of NAC on the long-term pulmonary effects in H-exposed veterans of the Iran-Iraq War with positive results [5, 115] . In 2004 Ghanei and coworkers [116] reported on a study investigating the effect of daily oral 600 mg NAC and 500 mg clarithromycin treatments on veterans documented as having been exposed to H between 1985 and 1988. These veterans were diagnosed as having bronchiolitis obliterans that was non-responsive to high dose bronchodilator (salmeterol) therapy and inhaled corticosteroid (fluticasone propionate). At six months, in those patients exhibiting cough and sputum (10/17), all ten exhibited reduced rates of these symptoms. Forced expiratory volume over one minute (FEV1) was improved in 14 of 17 patients with an overall improvement of 10.6 +/-9.7% (p < 0.001 versus baseline), while forced vital capacity (FVC) was improved in 13 of 17 patients with an overall improvement of 12.9 +/-13.6% (p < 0.001 versus baseline). No placebo, clarithromycin-only, or NAC-only controls were carried out in this study and the authors volunteer that the results may have been due to the clarithromycin treatment. A much larger (144 patients) placebo controlled, double-blind study was conducted by the same group examining the effects of NAC in Iranian veterans "suffering from pulmonary disorders due to a single high dose of sulfur mustard gas during the Iran-Iraq conflict in 1988", but exhibiting normal pulmonary function (bronchiolitis obliterans syndrome class 0) [117] . Patients received 600 mg NAC or placebo twice daily for four months. No other drugs were allowed one month before or during the trial. However, salmeterol (50 µg twice daily) and fluticasone (250 µg twice daily) were taken by all patients during the study. N-Acetylcysteine was found to be highly effective statistically in reducing dyspnea, cough, and sputum, as well as improving pulmonary function endpoints such as FEV1 and FVC. The authors considered the findings to be remarkable due to the eighteen year gap between H exposure, and the relatively short four month NAC treatment regimen. This same group published a similar study using identical parameters, but this time with inclusion criteria requiring the trial patients to be exhibiting impaired J o u r n a l P r e -p r o o f pulmonary function (bronchiolitis obliterans syndrome class 1 and 2) due to the previous 1988 H exposure, and NAC being administered in 600 mg tablets three times daily [118] . Virtually identical conclusions were obtained. However, although these two studies appeared to have been run simultaneously by the same group, no comparisons were made between these two trials, even when reviewed by the same authors in later review papers [5, 115] .

In a retrospective five year follow-up study aimed at assessing the longer term 

The relative safety of NAC in humans has been well illustrated not only by its long history of clinical use, but also by the broad range of clinical applications that it is continually being tested for, or applied to. Research on NAC was initiated in the 1960s with reports of its effectiveness as a mucolytic in patients with cystic fibrosis (CF). Its development was the result of efforts to provide reduced thiols to break the disulphide bridges in the glycoprotein matrix of mucus in CF patients. Acetylation of cysteine yielded the much more stable NAC, which was shown to have significant mucolytic activity and clinical applications not only in the treatment of CF, but also in the prophylaxis and therapy of a number of other respiratory diseases [52] . In the 1970s, the ability of NAC to provide sulfhydryl moieties drove the effort to utilize it as a treatment for acetaminophen poisoning. During these studies, its protective role was also shown to include the provision of precursors to replenish GSH levels that had become depleted during phase two metabolism of acetaminophen [46] . The resultant widespread clinical use and success of NAC treatment in acetaminophen poisoning [49] [50] [51] has subsequently driven a large body of research investigating its therapeutic potential in a broad range of pathologies and disorders that are thought to be due to oxidative stress and GSH depletion such as bronchitis, doxorubicininduced cardiotoxicity, acute respiratory distress syndrome, radio-contrast-induced nephropathy, pesticide exposure, heavy metal toxicity, ischemia-reperfusion injury and dermatological J o u r n a l P r e -p r o o f conditions [46, 47, 120, 121] . N-acetylcysteine has also recently been proposed as both a preventative and therapeutic agent against COVID-19 due to its abilities to reduce the excessive mucus production, GSH depletion, oxidative stress and inflammation in the lungs that this virus causes [122] [123] [124] [125] [126] [127] , and several clinical trials are being carried out to assess NAC's efficacy against this disease [128] [129] [130] [131] . Interestingly, it has also been noted "that there are some similarities in the pathogenesis of SARS-CoV-2 and mustard gas in immune system disruption and pulmonary infection" [132] , including up-regulation of lung angiotensin-converting enzyme (ACE2), the receptor for SARS-CoV-2. The authors speculate that these commonalities will lead to increased susceptibility and more severe outcomes in Iranian survivors of H exposure to COVID-19 [132] .

The mechanistic complexity of NAC has become increasingly obvious and with the revelation that in addition to its antioxidant and GSH stabilizing attributes, it also impacts antiinflammatory pathways, mitochondrial function, apoptosis and neurogenesis, there has been growing evidence that this drug can also be of utility in treating a host of psychiatric and neurological disorders. Implicit in much of this work have been the discoveries that NAC also impacts neurotransmission not only through facilitation of dopamine release, but also through regulation of NMDA and AMPA due to NAC-induced activation of cysteine/glutamate antiporter activity and subsequent elevations in glutamate levels. Trials using NAC to treat a multitude of neuropsychiatric disorders have been carried out and have yielded positive evidence for its use in the treatment of Alzheimer's and Parkinson's diseases, autism, compulsive and grooming disorders, depression, bipolar disorder, schizophrenia, cocaine and cannabis dependence [53, [133] [134] [135] [136] [137] [138] . In a recent report reviewing NAC safety and efficacy as a protectant against traumatic brain injury (TBI), the authors found "moderate quality of evidence of efficacy J o u r n a l P r e -p r o o f and safety of the use of NAC and NACA in pre-clinical studies" and very limited clinical research in TBI patients [56] . They concluded that the available information warranted further animal work and clinical trials.

Deepmala and coworkers [134] reviewed clinical trials using NAC in neurological and psychiatric diseases, and highlighted the high dosages of this drug that can be tolerated, as well as the potential side effects of this drug. The trials reviewed used daily dosages ranging from 0.6 to 6 grams/day with the majority of the studies using 2.0-2.4 grams/day. Durations of the trials ranged from 2 days to 60 months, with positive outcomes in all cases. Side effects were rare in these studies, and very few reported were severe enough to necessitate discontinuation of NAC treatment. Gastrointestinal symptoms were the most common side effects and included mild abdominal pain and/or discomfort, nausea, vomiting, heartburn, flatulence, cramps and diarrhoea. Neurological side effects included headache and right hand tingling. Isolated instances of adverse effects also included rash, pruritus, fatigue, dry mouth, muscle pains, insomnia, nasal congestion, runny nose, restlessness, dizziness and irritability [134] . They concluded that given NAC's long track record of safety, tolerability, affordability, availability and positive but still preliminary results, there is a requirement for well designed, larger controlled studies for its use in a variety of different psychological and neurological disorders, a theme echoed in other reviews of NAC in these areas [53, 56, [133] [134] [135] [136] [137] [138] .

For over one hundred years, researchers have endeavoured to understand the mechanism of toxic action of H and to develop medical countermeasures against it. Although a great deal has been learned as to how this CW agent disrupts a broad range of cellular, biochemical and J o u r n a l P r e -p r o o f molecular pathways, the links between H exposure and toxic effects have as yet to be fully understood. Of the many potential candidate molecules investigated for potential protective efficacy against H, NAC possesses the most robust record both in terms of safety and of efficacy.

It is available as an over-the-counter nutritional supplement, and is also considered to be a safe and well tolerated medication for a host of diseases. Although, originally investigated for its direct antioxidant activities and maintenance of intracellular GSH levels, NAC also appears to [9] Sezigen, S., Ivelik, K., Ortatatli, M., Almacioglu, M., Demirkasimoglu, M. and Eyison, R.K.

(2019). Victims of chemical terrorism, a family of four who were exposed to sulfur mustard.

Toxicol. Lett. 303, 9-15. [11] Dacre, J.C. and Goldman, M. (1996) . Toxicology and pharmacology of the chemical warfare agent sulfur mustard. Pharmacol. Rev. 48, 289-325. 

The Medical Aspects of Chemical Warfare

Veterans at Risk: The Health Effects of Mustard Gas and Lewisite

Medical Defense Against Mustard Gas: Toxic Mechanisms and Pharmacological Implications

Textbook of Military Medicine. Part I. Warfare, Weaponry and the Casualty

Potential utility of N-acetylcysteine for treating mustard lung

Acute intensive care unit management of mustard gas victims: the Turkish experience

Mental health status following severe sulfur mustard exposure: a long-term study of Iranian war survivors

Long-term hematological and immunological complications of sulfur mustard poisoning in Iranian veterans

A review on delayed toxic effects of sulfur mustard in Iranian veterans

Long-term effects of sulfur mustard on civilians'mental health 20 years after exposure (The Sardasht-Iran Cohort Study)

Role of oxidative stress and antioxidant therapy in acute and chronic phases of sulfur mustard injuries: a review

Oxidants and antioxidants in sulfur mustard-induced injury

Antioxidants as potential medical countermeasures for chemical warfare agents and toxic industrial chemicals

Sulfur mustard toxicity following dermal exposure. Role of oxidative stress, and antioxidant therapy

Role of oxidative stress in sulfur mustard-induced pulmonary injury and antioxidant protection

Molecular toxicology of sulphur mustard-induced cutaneous inflammation and blistering

Effects of bis 2-chloroethyl sulphide on ATP receptor mediated responses of the rat vas deferens: Possible relationship to cytotoxicity

Molecular bases for mustard-induced vesication

Signaling molecules in sulfur mustard-induced cutaneous injury

Ionic dependence of sulphur mustard cytotoxicity

Mechanisms mediating the vesicant actions of sulfur mustard after cutaneous exposure

N-Acetyl-L-cysteine as prophylaxis against sulfur mustard

N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why

N-Acetyl cysteine functions as a fast-acting antioxidant by triggering intracellular H 2 S and sulfane sulfur production

Existing and potential therapeutic uses for Nacetylcysteine: The need for conversion to intracellular glutathione for antioxidant benefits

The chemistry and biological activities of N-acetylcysteine

N-Acetylcysteine: Antioxidant, aldehyde scavenger, and more

Acetylcysteine for acetaminophen poisoning

Acetominophen -Dose-dependent drug hepatotoxicity and acute liver failure in patients

Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review

Mechanisms of Nacetylcysteine in the prevention of DNA damage and cancer, with special reference to smokingrelated endpoints

The promise of N-acetylcysteine in neuropsychiatry

Brain targeted low molecular weight hydrophobic antioxidant compounds

Antioxidant and free radical scavenging properties of N-acetylcysteine amide (NACA) and comparison with N-acetylcysteine (NAC)

Systematic review of human and animal studies examining the efficacy and safety of Nacetylcysteine (NAC) and N-acetylcysteine amide (NACA) in traumatic brain injury: Impact on neurofunctional biomarkers of oxidative stress and inflammation

Comparative toxic effect of nitrogen mustards (HN-1, HN-2, and HN-3) and sulfur mustard on hematological and biochemical variables and their protection by DRDE-07 and its analogues

An investigation on protective effect of N-acetyl-L-cysteine against acute intoxication of sulfur mustard in mice. Abstract

The distribution kinetics of topical 14C-sulfur mustard in rabbit ocular tissues and the effect of acetylcysteine

Sulfur mustard induces apoptosis and necrosis in endothelial cells

N-Acetylcysteine and endothelial cell injury by sulfur mustard

Efficient protection of human bronchial epithelial cells against sulfur and nitrogen mustard cytotoxicity using drug combinations

Protective potential of different compounds and their combinations with MESNA against sulfur mustard-induced cytotoxicity and genotoxicity

Cysteine esters protect cultured rodent lung slices from sulphur mustard

Treatment of sulfur mustard (HD)-induced lung injury

Mustard gas inhalation injury: Therapeutic Strategy

N-Acetyl-L-cysteine protects against inhaled sulfur mustard poisoning in the large swine

Toxicokinetics of sulfur mustard and its DNA-adducts in the hairless guinea pig

Comparative toxicity of mono-and bifunctional alkylating homologues of sulphur mustard in human skin keratinocytes

N-acetylcysteine protects lymphocytes from nitrogen mustard-induced apoptosis

Potentiation of nitrogen mustard cytotoxicity to leukemia cells by sulfur-containing compounds administered in vivo

Chlorambucil (nitrogen mustard) induced impairment of early vascular endothelial cell migration -Effects of α-linolenic acid and Nacetylcysteine

CEES-induced ROS accumulation regulates mitochondrial complications and inflammatory response in keratinocytes

Protection from cytotoxic effects induced by the nitrogen mustard mechlorethamine on human epithelial cells in vitro

Role of nicotinamide adenine dinucleotide phosphate oxidase in mediating vesicant-induced interleukin-6 secretion in human airway epithelial cells

Ability of antioxidant liposomes to prevent acute and progressive pulmonary injury

Protection from halfmustard-gas-induced acute lung injury in the rat

Attenuation of half sulfur mustard gas-induced acute lung injury in rats

Prophylactic protection by N-acetylcysteine against the pulmonary injury induced by 2-chloroethyl ethyl sulfide, a mustard analogue

Protection of half sulfur mustard gas-induced lung injury in guinea pigs by antioxidant liposomes

Role of MAPK/AP-1 signaling pathway in the protection of CEES-induced lung injury by antioxidant liposome

Antioxidant liposomes protect against CEES-induced lung injury by decreasing SAF-1/MAZmediated inflammation in the guinea pig lung

Evidence of hair loss after subacute exposure to 2-chloroethyl ethyl sulfide, a mustard analog, and beneficial effects of N-acetyl cysteine

Aerosolized administration of Nacetylcysteine attenuates lung fibrosis induced by bleomycin in mice

Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in rats

Protection by cysteine esters against chemically induced pulmonary oedema

Effects of antioxidant N-acetylcysteine against paraquat-induced oxidative stress in vital tissues of mice

Protective effects of N-acetylcysteine treatment post acute paraquat intoxication in rats and in human lung epithelial cells

N-Acetylcysteine attenuates phosgene-induced acute lung injury via up-regulation of Nrf2 expression

Protective effects of N-acetylcysteine treatment after phosgene exposure in rabbits

The role of N-acetylcysteine in the management of acute and chronic pulmonary complications of sulfur mustard: a literature review

Efficacy of concomitant administration of clarithromycin and acetylcysteine in bronchiolitis obliterans in seventeen sulfur mustardexposed patients: An open-label study

Nacetylcysteine improves the clinical conditions of mustard gas-exposed patients with normal pulmonary function test

Therapeutics effect of N-acetyl cysteine on mustard gas exposed patients: Evaluating clinical aspect in patients with impaired pulmonary function test

Long term follow-up of sulfur mustard related bronchiolitis obliterans treatment

A minireview on N-acetylcysteine: An old drug with new approaches

The potential uses of N-acetylcysteine in dermatology: A review

War to the knife" against thromboinflammation to protect endothelial function of COVID-19 patients

N-Acetylcysteine: A potential therapeutic agent for SARS-C0V-2

Rationale for the use of Nacetylcysteine in both prevention and adjuvant therapy of COVID-19

N-acetylcysteine: A potential therapeutic agent in COVID-19 infection

N-acetylcysteine as a potential treatment for novel coronavirus disease 2019

Tackle the free radicals damage in COVID-19

A study of N-acetylcysteine in patients with COVID-19 infection

Efficacy of N-acetylcysteine (NAC) in preventing COVID-19 from progressing to severe disease

Inflammatory regulation effect of NAC on COVID-19 treatment (INFECT-19)

Antioxidant therapy for COVID-19 study (GSHSOD-COVID)

Are Iranian sulfur mustard gas-exposed survivors more vulnerable to SARS-CoV-2? Some similarity in their pathogenesis

Systematic review of Nacetylcysteine in the treatment of addictions

Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review

Potential role of N-acetylcysteine in the management of substance use disorders

N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects

N-Acetylcysteine for the treatment of psychiatric disorders: A review of current evidence

Overview on the effects of Nacetylcysteine in neurodegenerative diseases

 Figure 5 Chemical structures of L-cysteine, N-acetylcysteine (NAC), N-acetylcysteine amide (NACA) and glutathione (GSH). Although NAC has been shown to interact directly with H, this role is believed to be minor in preventing its effects. The major role for NAC or its amide derivative NACA, is as pro-drugs that act to up-regulate glutathione (GSH) levels, especially when they are depleted. The elevated GSH levels then ameliorate H-induced oxidative stress, inflammation and/or cytotoxicity.J o u r n a l P r e -p r o o f Table1: Effect of N-acetylcysteine against mustard vesicant treatment in tissue culture models.